Case Reports
doi: 10.1164/rccm.201502-0372LE.
Delamanid and Bedaquiline Resistance in Mycobacterium tuberculosis Ancestral Beijing Genotype Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Refugee
Affiliations
- PMID: 26829425
- DOI: 10.1164/rccm.201502-0372LE
Item in Clipboard
Case Reports
Delamanid and Bedaquiline Resistance in Mycobacterium tuberculosis Ancestral Beijing Genotype Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Refugee
Am J Respir Crit Care Med.
.
Free article
No abstract available
Comment in
-
Preventing Acquired Resistance to Bedaquiline and Delamanid in Multidrug-Resistant Tuberculosis Treatment Requires Optimal Management.Am J Respir Crit Care Med. 2016 Nov 1;194(9):1170-1171. doi: 10.1164/rccm.201604-0841LE. Am J Respir Crit Care Med. 2016. PMID: 27797614 No abstract available.
-
Reply: Call for Regular Susceptibility Testing of Bedaquiline and Delamanid.Am J Respir Crit Care Med. 2016 Nov 1;194(9):1171-1172. doi: 10.1164/rccm.201605-1065LE. Am J Respir Crit Care Med. 2016. PMID: 27797620 No abstract available.
Similar articles
-
In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China.Antimicrob Agents Chemother. 2017 Sep 22;61(10):e00900-17. doi: 10.1128/AAC.00900-17. Print 2017 Oct. Antimicrob Agents Chemother. 2017. PMID: 28739779 Free PMC article.
-
Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.Ann Lab Med. 2018 Nov;38(6):563-568. doi: 10.3343/alm.2018.38.6.563. Ann Lab Med. 2018. PMID: 30027700 Free PMC article.
-
Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.Clin Infect Dis. 2019 Sep 13;69(7):1229-1231. doi: 10.1093/cid/ciz074. Clin Infect Dis. 2019. PMID: 30933266
-
A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis.J Clin Lab Anal. 2024 Aug;38(15-16):e25091. doi: 10.1002/jcla.25091. J Clin Lab Anal. 2024. PMID: 39431709 Free PMC article. Review.
-
Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician's perspective.Future Microbiol. 2020 Jun;15:779-799. doi: 10.2217/fmb-2019-0309. Epub 2020 Jul 23. Future Microbiol. 2020. PMID: 32700565 Review.
Cited by
-
Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.J Antimicrob Chemother. 2020 Aug 1;75(8):2031-2043. doi: 10.1093/jac/dkaa136. J Antimicrob Chemother. 2020. PMID: 32361756 Free PMC article.
-
Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs.Genome Med. 2019 Jun 24;11(1):41. doi: 10.1186/s13073-019-0650-x. Genome Med. 2019. PMID: 31234910 Free PMC article.
-
Investigation of Clofazimine Resistance and Genetic Mutations in Drug-Resistant Mycobacterium tuberculosis Isolates.J Clin Med. 2022 Mar 30;11(7):1927. doi: 10.3390/jcm11071927. J Clin Med. 2022. PMID: 35407536 Free PMC article.
-
Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium tuberculosis.Front Microbiol. 2021 Oct 7;12:717045. doi: 10.3389/fmicb.2021.717045. eCollection 2021. Front Microbiol. 2021. PMID: 34690963 Free PMC article. Review.
-
Adduct Formation of Delamanid with NAD in Mycobacteria.Antimicrob Agents Chemother. 2020 Apr 21;64(5):e01755-19. doi: 10.1128/AAC.01755-19. Print 2020 Apr 21. Antimicrob Agents Chemother. 2020. PMID: 32152081 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
